Ireland has become the first country to recruit patients as part of the new global FaReal study to evaluate the effectiveness, safety, clinical insights and treatment patterns of faricimab ▼ in the real-world treatment of neovascular age related macular degeneration (nAMD) or diabetic macular edema (DME) in at least one eye¹. The study will take place in real-world clinical environments over a two year period.
The study is being conducted at the Institute for Eye Surgery (IoES), UMPC Whitfield Hospital in Waterford by Prof Maged Habib, Mr Marin Belak and Dr Emmanuel Ankamah, who have already recruited the first patients. In total, close to 50 Irish patients will be included in the trial in Waterford and three other sites across Ireland as part of an expected trial of 850 patients across 17 countries1.
It’s an incredible achievement for our team to be the first site globally to go-live and recruit for the FaReal study. This again proves that Ireland is capable of delivering the highest quality of clinical research by working very closely with our partners in Roche Ireland. Mr. Marin Belak recruited our first patient and we are now very eager to complete enrolment and gain a deeper understanding of the potential that faricimab has to improve treatment in nAMD and DME.
While Ireland is a renowned innovation hub for the pharma sector, Ireland is attracting fewer clinical trials than some European countries with similar populations and economic performances. The FaReal Study shows us that healthcare providers in Irish hospitals have the ability to drive world-class research. At Roche, we believe that Ireland can play a leading role in the provision of clinical trials in Europe. Patients in Ireland deserve a strong clinical research infrastructure to provide access to sometimes life-saving treatments.
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
In the event of a suspected adverse event, please report it to:
The Drug Surveillance Centre Roche Products (Ireland)
Limited Telephone:
Email:
Alternatively, suspected adverse reactions should be reported to:
References